Survival analyses showed that among ALS patients, carriers of CAV1/2 enhancer mutations had longer survival compared to non-carriers, with a median survival difference of 345 days in the Project MinE dataset. This evidence concerns the gene CAV1 and amyotrophic lateral sclerosis.